PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer

[1]  J. Machan,et al.  Expression of PD‐L1, indoleamine 2,3‐dioxygenase and the immune microenvironment in gastric adenocarcinoma , 2018, Histopathology.

[2]  T. Fujiwara,et al.  Accuracy of four mononucleotide-repeat markers for the identification of DNA mismatch-repair deficiency in solid tumors , 2018, Journal of Translational Medicine.

[3]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[4]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[5]  P. Keegan,et al.  First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. , 2017, The New England journal of medicine.

[6]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[7]  Xinlong Li,et al.  PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis , 2017, PloS one.

[8]  H. Bae,et al.  Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology , 2017, World journal of gastrointestinal oncology.

[9]  Qi Zhou,et al.  Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis , 2017, Oncotarget.

[10]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[11]  Su Jin Heo,et al.  PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients , 2016, Scientific Reports.

[12]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[13]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[14]  Steven J. M. Jones,et al.  Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer , 2016, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  Xiaoshan Feng,et al.  Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis , 2016, OncoTargets and therapy.

[16]  M. Shimada,et al.  Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection , 2016, Gastric Cancer.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  K. Hirakawa,et al.  Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. , 2015, Anticancer research.

[19]  Jian Huang,et al.  PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.

[20]  Matteo Brunelli,et al.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.

[21]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[22]  Yan Wang,et al.  Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis. , 2015, Molecular and clinical oncology.

[23]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[24]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[25]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[26]  M. Gulley.  Genomic assays for Epstein–Barr virus-positive gastric adenocarcinoma , 2015, Experimental & Molecular Medicine.

[27]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[28]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[29]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[30]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[31]  K. Bickenbach,et al.  Comparisons of Gastric Cancer Treatments: East vs. West , 2012, Journal of gastric cancer.

[32]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[33]  C. Boland,et al.  An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers , 2010, PloS one.

[34]  F. Schmidt.  Meta-Analysis , 2008 .

[35]  D. Kennedy.  Breakthrough of the Year , 2004, Science.

[36]  O. Dogar.  in with a randomised, double-blind, placebo-controlled phase 3 trial , 2021 .

[37]  Sang-Hoon Ahn,et al.  Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer , 2014, Gastric Cancer.

[38]  Japanese Gastric Cancer Association.  Japanese classification of gastric carcinoma: 3rd English edition , 2011, Gastric Cancer.

[39]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[40]  A. Jemal,et al.  Global Cancer Statistics , 2011 .